Impact of treatment patterns and sequencing on clinical and economic outcomes in patients with metastatic urothelial cancer: IMPACT UC II study
Results provide baseline data for future studies evaluating the impact of newer treatment options for patients with mUC.
Authors
- Valerie Morris (ORCID: https://orcid.org/0000-0002-8105-585X)
- Amy M. Nguyen (ORCID: https://orcid.org/0009-0008-2712-9871)
- Louise B. Murphy (ORCID: https://orcid.org/0000-0003-3919-0721)
- Brandon J. Diessner (ORCID: https://orcid.org/0000-0002-3725-3410)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Melissa Kirker
- Norbek Gharibian
- Abhijeet Bhanegaonkar
- John White (ORCID: https://orcid.org/0000-0001-7895-4443)
Institutions
- Emory University (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Pfizer (United States) (US)
- Piedmont Cancer Institute (US)
- Merck Serono S.A. (Switzerland) (CH)
- Optum (United States) (US)
- Merck Serono S.p.A. (Italy) (IT)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/oncolo/oyaf249
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- American Society of Clinical Oncology
- Merck KGaA
- EMD Serono